Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials

医学 危险系数 免疫抑制 不利影响 泼尼松龙 临床试验 肿瘤科 皮质类固醇 比例危险模型 内科学 析因分析 置信区间
作者
Rik Jasper Verheijden,Jolien S. de Groot,Babs O. Fabriek,Miki N. Hew,Anne Maria May,Karijn P.M. Suijkerbuijk
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (31): 3713-3724 被引量:134
标识
DOI:10.1200/jco.24.00191
摘要

PURPOSE Retrospective studies suggest that immunosuppressive treatment of immune-related adverse events (irAEs) impairs survival in patients with melanoma who received immune checkpoint inhibitors. Here, we study this association across tumor types using data from six international phase II/III registrational trials. METHODS A post hoc analysis was performed on individual patient data from the anti–programmed cell death-1 (anti–PD-1) + anti–cytotoxic T lymphocyte–associated protein-4 (anti–CTLA-4) treatment arms of six clinical trials (CheckMate-067, -142, -214, -648, -743, and -9LA). Among patients who received systemic immunosuppression for treatment-related adverse events (trAEs), associations of peak and cumulative corticosteroid dose, and use of second-line immunosuppression with overall survival (OS) and progression-free survival (PFS) were assessed using multilevel Cox regression with adjustment for age and sex. RESULTS Of the 1,959 patients who received anti–PD-1 + anti–CTLA-4 therapy, 834 patients who were treated with immunosuppression for trAEs were included. Eight hundred and thirty-two patients (100%) received corticosteroids and 81 patients (10%) received second-line immunosuppressants. High corticosteroid peak dose was associated with worse PFS: adjusted hazard ratio (HR adj ), 1.15 (95% CI, 1.02 to 1.29) for 1 versus 0.5 mg/kg prednisolone and HR adj , 1.43 (95% CI, 1.05 to 1.96) for 2 versus 0.5 mg/kg. Similar effects were observed for OS: HR adj , 1.21 (95% CI, 1.06 to 1.39) and HR adj , 1.66 (95% CI, 1.17 to 2.37) for 1 and 2 versus 0.5 mg/kg, respectively. Cumulative corticosteroid dose was not associated with survival. HR adj of use of second-line immunosuppression was 1.23 (95% CI, 0.90 to 1.68) for PFS and 1.25 (95% CI, 0.88 to 1.77) for OS. CONCLUSION Higher corticosteroid peak dose for trAEs is associated with worse survival across tumor types, while cumulative dose is not. Too few patients received second-line immunosuppressants to confirm or reject an association with survival. These data argue for a reconsideration of irAE management approaches, starting with lower corticosteroid dose whenever feasible.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
怎么忘了完成签到,获得积分10
刚刚
TaraScott912发布了新的文献求助40
1秒前
顾矜的应助被柯羲采纳,获得10
1秒前
1秒前
桐桐的应助被qqasd采纳,获得10
2秒前
打打的应助被草根喵采纳,获得10
2秒前
2秒前
2秒前
yeye完成签到,获得积分10
2秒前
3秒前
东方不败发布了新的文献求助30
3秒前
风吹麦浪发布了新的文献求助10
4秒前
4秒前
可可完成签到,获得积分20
4秒前
4秒前
RJ发布了新的文献求助10
4秒前
斯文败类的应助被科研通管家采纳,获得10
4秒前
5秒前
完美世界的应助被科研通管家采纳,获得10
5秒前
5秒前
灞波儿奔的应助被科研通管家采纳,获得10
5秒前
5秒前
怪默发布了新的文献求助10
5秒前
5秒前
丘比特的应助被科研通管家采纳,获得10
5秒前
wating完成签到,获得积分10
5秒前
Haku发布了新的文献求助10
5秒前
5秒前
情怀的应助被科研通管家采纳,获得10
5秒前
5秒前
强健的元冬完成签到,获得积分10
5秒前
灞波儿奔的应助被科研通管家采纳,获得10
5秒前
5秒前
加冰完成签到,获得积分10
6秒前
南极星人给南极星人的求助进行了留言
6秒前
Ryo的应助被潇笑采纳,获得10
6秒前
NexusExplorer的应助被科研通管家采纳,获得10
6秒前
ze发布了新的文献求助10
6秒前
无极微光的应助被科研通管家采纳,获得20
6秒前
吴晨曦发布了新的文献求助10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176174
求助须知:如何正确求助?哪些是违规求助? 9567656
关于积分的说明 21793895
捐赠科研通 7770887
什么是DOI,文献DOI怎么找? 3431991
关于科研通互助平台的介绍 2556313
邀请新用户注册赠送积分活动 2477540